Arrowstreet Capital’s Nektar Therapeutics NKTR Stock Holding History

Arrowstreet Capital’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-10,033	Closed	-$3.25M	–	2036
2019 Q4	$3.25M	Buy	+10,033	New	+$2.91M	0.01%	980
2014 Q4	–	Sell	-1,041	Closed	-$188K	–	1305
2014 Q3	$188K	Sell	1,041 -353	-25%	-$67.6K	﹤0.01%	944
2014 Q2	$268K	Buy	+1,394	New	+$247K	﹤0.01%	892

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Arrowstreet Capital's NKTR Position: Q1 2020 in Review

Arrowstreet Capital sold out of Nektar Therapeutics (NKTR) in Q1 2020, closing a stake of 10,033 shares — an estimated $3.25M sold.

Arrowstreet Capital first reported a position in NKTR in Q2 2014 and held it in 3 quarters. The position peaked at $3.25M in Q4 2019. 245 funds tracked by Wall St. Rank hold NKTR as of Q1 2020.

Arrowstreet Capital reported no remaining Nektar Therapeutics position as of Q1 2020 after selling out during the quarter.
Arrowstreet Capital sold 10,033 Nektar Therapeutics shares in Q1 2020, an estimated $3.25M.
Arrowstreet Capital first reported a position in Nektar Therapeutics in Q2 2014 and held it in 3 quarters.
Arrowstreet Capital's Nektar Therapeutics position peaked at $3.25M in Q4 2019.
245 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2020.

Based on Arrowstreet Capital's 13F filing for Q1 2020, filed 15 May 2020.